|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
<i>ALK</i> was first identified in a subset of T-cell lymphomas with anaplastic large cell lymphoma (ALCL) morphology (ALK+ ALCL), the vast majority of which harbor the well-characterized nucleophosmin (NPM)-ALK fusion protein.
|
27879258 |
2017 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) exhibiting the t(2;5) translocation is characterized by the resulting expression of the oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) gene product.
|
11801565 |
2002 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphomas lacking ALK are clinically heterogeneous and their pathogenesis is unknown.
|
15948116 |
2005 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) is a subtype of aggressive non-Hodgkin's lymphoma that is characterized by expression of CD30 and the NPM/ALK chimeric protein, which is generated by t(2;5)(p23;q35).
|
16533741 |
2005 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) is an aggressive T-lineage lymphoma harboring chromosomal translocations involving the anaplastic lymphoma kinase (ALK) tyrosine kinase.
|
16785248 |
2006 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
ALCL-negative tumours had a significantly worse prognosis than ALK-positive.
|
18275429 |
2008 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Systemic anaplastic large cell lymphoma is composed of two disease groups based on the presence or absence of anaplastic lymphoma kinase overexpression.
|
19509496 |
2009 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK)-positive, is uncommon in infancy.
|
19863446 |
2010 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) is recognized as 2 distinct diseases: anaplastic lymphoma kinase (ALK)+ ALCL and ALK- ALCL.
|
19864230 |
2009 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK)-positive (ALK+ ALCL) is an aggressive CD30-positive T-cell lymphoma that exhibits a chromosomal translocation involving the ALK gene and the expression of ALK protein.
|
22440390 |
2012 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Anaplastic large-cell lymphomas (ALCLs) encompass at least 2 systemic diseases distinguished by the presence or absence of anaplastic lymphoma kinase (ALK) expression.
|
23801630 |
2013 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Systemic anaplastic large cell lymphoma is a category of T-cell non-Hodgkin's lymphoma which can be further subdivided into two distinct entities (ALK(+) and ALK(-)) based on the presence or absence of ALK gene rearrangements.
|
23975180 |
2014 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Systemic anaplastic large cell lymphoma (ALCL) is a distinct disease classification provisionally sub-divided into ALCL, Anaplastic Lymphoma Kinase (ALK)(+) and ALCL, ALK(-) entities.
|
25475421 |
2015 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) is divided into two systemic diseases according to the expression of the anaplastic lymphoma kinase (ALK).
|
25688981 |
2015 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Anaplastic large cell lymphomas (ALCLs) are rare CD30+ peripheral T-cell lymphomas (PTCLs) classified according to the expression of the anaplastic lymphoma kinase (ALK+) protein or not (ALK-).
|
28485010 |
2017 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Systemic anaplastic large-cell lymphoma (ALCL) is a childhood T cell neoplasm defined by the presence or absence of translocations that lead to the ectopic expression of anaplastic lymphoma kinase (ALK), with nucleophosmin-ALK (NPM-ALK) fusions being the most common.
|
29581862 |
2018 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) is a type of T-cell lymphoma that can be divided into two categories: anaplastic lymphoma kinase-positive (ALK+) and ALK-negative.Gastrointestinal ALK+ ALCL is rare.
|
31423437 |
2019 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity.
|
7655022 |
1995 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity.
|
9209450 |
1997 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Anaplastic large cell lymphoma: a distinct molecular pathologic entity: a reappraisal with special reference to p80(NPM/ALK) expression.
|
9414185 |
1997 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
ALK(-) ALCL occurs in older patients, affecting both genders equally and having an unfavorable prognosis.
|
11090048 |
2000 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
ALK was detected in 21 of 66 (31.8%) ALCLs.
|
11485911 |
2001 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Anaplastic lymphoma kinase (ALK) is frequently observed in systemic anaplastic large cell lymphoma (ALCL), mostly in childhood or adolescence, but only rarely in primary cutaneous cases.
|
15214912 |
2004 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
ALK positive systemic nodal ALCL are associated with a good prognosis.
|
15713979 |
2005 |